Eva De Lago

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Selective Brain-Penetrant TTBK1 Inhibitors Modulate TDP-43 Pathology and Rescue Cognitive Deficits in a Mouse Model of TDP-43 Proteinopathy.

Selective Brain-Penetrant TTBK1 Inhibitors Modulate TDP-43 Pathology and Rescue Cognitive Deficits in a Mouse Model of TDP-43 Proteinopathy.

Journal: Journal of medicinal chemistry

Published: June 14, 2026

Assessment of the therapeutic effect of IGS2.7, a CK1δ protein kinase inhibitor, in combination with riluzole for the treatment of ALS-associated TDP-43 proteinopathy.

Assessment of the therapeutic effect of IGS2.7, a CK1δ protein kinase inhibitor, in combination with riluzole for the treatment of ALS-associated TDP-43 proteinopathy.

Journal: Neuropharmacology

Published: October 04, 2025

Ageing, Neurodegeneration and the Endocannabinoid System.

Ageing, Neurodegeneration and the Endocannabinoid System.

Journal: Current topics in behavioral neurosciences

Published: July 24, 2025

Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis.

Preclinical evaluation of cannabidiolic acid as a neuroprotective agent in TDP-43 transgenic mice, an experimental model of amyotrophic lateral sclerosis.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: April 14, 2025

Development of Novel Neuroprotective Agents Targeting GPCR Using in Vitro Assays.

Development of Novel Neuroprotective Agents Targeting GPCR Using in Vitro Assays.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: March 11, 2025

Relevance of a peripheral site of action outside the brain-blood barrier for the beneficial effects of CB2 receptor activation in experimental ALS in male mice.

Relevance of a peripheral site of action outside the brain-blood barrier for the beneficial effects of CB2 receptor activation in experimental ALS in male mice.

Journal: Cell communication and signaling : CCS

Published: January 27, 2025

Beneficial Effect of Dimethyl Fumarate Drug Repositioning in a Mouse Model of TDP-43-Dependent Frontotemporal Dementia.

Beneficial Effect of Dimethyl Fumarate Drug Repositioning in a Mouse Model of TDP-43-Dependent Frontotemporal Dementia.

Journal: Antioxidants (Basel, Switzerland)

Published: July 30, 2024

Enhancing Drug Discovery and Development through the Integration of Medicinal Chemistry, Chemical Biology, and Academia-Industry Partnerships: Insights from Roche's Endocannabinoid System Projects.

Enhancing Drug Discovery and Development through the Integration of Medicinal Chemistry, Chemical Biology, and Academia-Industry Partnerships: Insights from Roche's Endocannabinoid System Projects.

Journal: Chimia

Published: June 09, 2024

Involvement of CB1 and CB2 receptors in neuroprotective effects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male mice.

Involvement of CB1 and CB2 receptors in neuroprotective effects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male mice.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: October 31, 2023

Discovery of Mitophagy Inhibitors with Therapeutic Potential in Different Familial Amyotrophic Lateral Sclerosis Mutations.

Discovery of Mitophagy Inhibitors with Therapeutic Potential in Different Familial Amyotrophic Lateral Sclerosis Mutations.

Journal: International journal of molecular sciences

Published: September 29, 2022

Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice.

Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice.

Journal: Journal of neuroinflammation

Published: August 24, 2022

New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.

New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.

Journal: Biomolecules

Published: July 18, 2022

Showing 1-12 of 35

Last Updated: 09/26/2026